STELLAR

Clinical Trial

NCT03780257 Completed

STELLAR

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RetinitisPigmentosa Due to Mutations in Exon 13 of the USH2A Gene (Stellar)

Phase 3

Interventional

Disease

Disease type

Hereditary retinal disease

Retinitis Pigmentosa

Usher Syndrome

Orphan drug recognition

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

27/03/2019

Closing date

14/10/2021

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Main investigators

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)